Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed

Caissargues, May 12, 2022

 

In €k 2020-2021 2021-2022 Change 3rd quarter revenue 111,669 118,446 +6.1% 9-month revenue 333,033 341,491 +2.5%

 

 

Group

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development

QUANTUM GENOMICS : Publication of the Universal Registration Document

Publication of the Universal Registration Document

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the

QUANTUM GENOMICS : Update of Shareholding Situation Following April 27, 2022 Capital Raise

Update of Shareholding Situation Following April 27, 2022 Capital Raise

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a

Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR

Quantum Genomics announces successful capital raising with a gross sum of approximately €15.6 M€

  • Quantum Genomics has equipped itself with new financial means to pursue the development of
Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M

Quantum Genomics Raises a Gross Amount of Approximately € 15 M

  • Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases

Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

BOIRON : 2022 first quarter sales

(Unaudited data)

In thousands of euros 2022 2021 Variation at current exchange rates Variation at constant exchange rates France 77,055 51,518 +49.6% +49.6% Europe
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new

QUANTUM GENOMICS : Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new

BOIRON : 2021 results

The Board of Directors of BOIRON, at its meeting on March 9, 2022 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31

THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
  • · New milestone for NeuroLead, the active agent screening platform
  • · New publications in scientific journals
  • · Start of Phase I/II clinical trial for Batten disease

Lyon, 28 February 2022

THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS

Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates

BOIRON : 2021 sales

(Unaudited data)

QUARTERLY ACTIVITY IN 2021 (VARIATION AT CURRENT EXCHANGE RATES)

in thousands of euros 1st quarter 2nd quarter 3rd quarter 4th quarter 2021 2020 Var. 2021
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE

Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Brand Messaging and Overlooked Digital Marketing Trends
The year that saw digital marketers and public relations officers rapidly adapting and changing marketing efforts - but some trends have been overlooked.  Digital marketers and PR officers had a
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022

Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction

Abbvie Inc - Technical Analysis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23878/Abbvie_logo.png
Abbvie Inc - Technical Analysis
Considering both the recent stock trend and the indicators signs combined with the fundamental analysis, Abbvie company tends to remain in hold position with a little growth in price. AbbVie Inc
Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.

Press release

Paris, December 6, 2021

Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.

  • Quantum Genomics will receive up to $20 M
Survey: International Nurses on the Front Lines of COVID-19 Care: https://mms.businesswire.com/media/20201201005032/en/841855/5/AMN-Logo.jpg
Survey: International Nurses on the Front Lines of COVID-19 Care


Nearly 90% of international nurses providing care in the United States have treated COVID-19 patients, while 17% have themselves contracted the coronavirus, according to a new survey.



Conducted

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:




  • Jereme Sylvain, Executive Vice President and Chief

QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON® QuantiFERON®-TB Gold Plus